

European Business Development Conference

Pharma and European Biotech – A valuable Collaboration to Improve Health 23 and 24 September 2013 / Dusseldorf / Germany

Company Profile: PAION AG

Contact Person: Dr Wolfgang Söhngen Address / PO Box: Martinstrasse 10-12

Postal Code / City: 52062 Aachen State: North Rhine-Westphalia

Country: Germany

Telephone: +49-241-4453-110

Fax: +49-241-4453-120

E-mail Address: w.soehngen@paion.com

Website: www.paion.com

Existing co-operations: Ono Pharmaceutical, Yichang Humanwell, Acorda Therapeutics, Hana

Pharm

Request for co-operations: Remimazolam an innovative short-acting general anaesthetic/sedative, M6G an active potent metabolite of morphine for post-operative pain, Solulin/PN 13 an improved variant of the human protein thrombomodulin for the treatment of haemophilia

About PAION

PAION AG is a publicly-listed biotech company headquartered in Aachen, Germany with a second site in Cambridge, UK. The company has a track record in developing hospital-based treatments for which there is substantial unmet medical need. PAION AG is transforming its business model from a pure development company to a specialty pharmaceutical company with a focus on anaesthesia products to take advantage of the unique profile of its main compound, Remimazolam.

About Remimazolam

Remimazolam is an innovative short-acting general anaesthetic/sedative. Due to its short duration of action and good controllability, it has a preferable efficacy and safety profile relative to other currently marketed anaesthesia compounds. The rapid offset of Remimazolam's effect is due to its metabolism by tissue esterase enzymes that are widely distributed throughout the body.

Remimazolam has potential in three indications:

- Procedural sedation
- General anaesthesia
- ICU sedation

Remimazolam is available for licensing outside Japan, China and South Korea, where the compound is partnered with Ono Pharmaceutical and Yichang Humanwell and Hana Pharm has an exclusive option.